The French index CAC 40 is about to witness a new merger. In fact Sanofi Aventis is about to arrange a friendly merger with the American company Bristol-Myers Squibb (BMS). Although this operation is not sure for the moment, it wouldn't be amazing to see such a merger as there have been a lot of mergers during previous years. Such a merger would enable this new group to become world number one.
Sanofi Aventis is the biggest European company in pharmaceutical sector.
It has been created by the non friendly fusion of Sanofi-Synthélabo and Aventis in 2005 thanks to the abnegation of Mr Deheck.
The announcement of a new merger has created a decrease in Sanofi Aventis shares value. There are different points of view regarding this merger. On the one hand, there are some advantages. These company indeed have complementary portfolios. And their merger would enable some synergies regarding their structures. Sanofi Aventis would increase it's turnover, and would have more power in USA.
On the other hand the decrease in shares value after the announcement of the merger is the proof that some analysts are skeptical. This merger could create some problems, because of the partnership between BMS and another company AstraZeneca.
Sanofi Aventis is the biggest European company in pharmaceutical sector.
It has been created by the non friendly fusion of Sanofi-Synthélabo and Aventis in 2005 thanks to the abnegation of Mr Deheck.
The announcement of a new merger has created a decrease in Sanofi Aventis shares value. There are different points of view regarding this merger. On the one hand, there are some advantages. These company indeed have complementary portfolios. And their merger would enable some synergies regarding their structures. Sanofi Aventis would increase it's turnover, and would have more power in USA.
On the other hand the decrease in shares value after the announcement of the merger is the proof that some analysts are skeptical. This merger could create some problems, because of the partnership between BMS and another company AstraZeneca.
No comments:
Post a Comment